CMS transparency rules and AI could bring “Expedia-like” drug price comparisons for consumers, but payer compliance to transparency rules remains low.
News|Articles|September 26, 2023
Potential Contamination Leads to Recall of VistaPharm’s Sucralfate
In patients who are immunocompromised, Bacillus cereus can result in life-threatening infections such as endocarditis and necrotizing soft tissue infections.
Advertisement
VistaPharm is recalling one lot of Sucralfate Oral Suspension, 1g/10mL, which is used to treat patients with duodenal ulcers, because of Bacillus cereus contamination in the product. Bacillus cereus is a Gram-positive bacteria found in food and cause food poisoning. But in patients who are immunocompromised, Bacillus cereus can result in life-threatening infections such as endocarditis and necrotizing soft tissue infections.
VistaPharm has not received any reports of adverse events. A contractor, Inmar, is conducting the recall.
The affected lot, 810300, has an expiration date of Oct. 31, 2023, and NDC number 66689-305-16.
Advertisement
Related to this article
A new Spherix Global Insights survey shows providers want administrative support for prior authorization while patients prioritize access and affordability
Pharmacy benefit managers are moving beyond formulary access to provide support programs for women's health. Here's how three PBMs — Judi Health, LucyRx and RxPreferred — are putting that strategy into practice.
Women face more gaps in healthcare than men, from missed screenings, undertreatment and biased coverage. PBMs are launching programs to address some of the gaps.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Texas A&M researchers discover promising therapy for fatty liver disease
2
Heather Burrell Ward, M.D., on personalizing TMS in schizophrenia
3
Low birth volume, finances tied to hospital obstetric unit closures
4
The hidden costs of routine radiology and how they can be addressed
5